Marshall T. Bell

Attenuation of spinal cord ischemia-reperfusion injury by specific α-2a receptor activation with dexmedetomidine.

Preservation of motor function after spinal cord ischemia and reperfusion injury through microglial inhibition.

Interruption of spinal cord microglial signaling by alpha-2 agonist dexmedetomidine in a murine model of delayed paraplegia.

Toll-like receptor 4-dependent microglial activation mediates spinal cord ischemia-reperfusion injury.

Dexmedetomidine, an α-2a adrenergic agonist, promotes ischemic tolerance in a murine model of spinal cord ischemia-reperfusion.